Safety and Tolerability of Subcutaneous Cladribine Therapy in Progressive Multiple Sclerosis
نویسندگان
چکیده
منابع مشابه
Safety and tolerability of subcutaneous cladribine therapy in progressive multiple sclerosis.
OBJECTIVE To evaluate the safety and tolerability of subcutaneous (s.c.) cladribine therapy in patients with chronic progressive multiple sclerosis (CPMS), and to evaluate the effects on lymphocyte subsets. BACKGROUND Cladribine, a synthetic antineoplastic agent with immunosuppressive effects, may favourably affect the course of CPMS. However results of a previous reported clinical trial show...
متن کاملSafety, tolerability and pharmacodynamics of a novel immunomodulator, MIS416, in patients with chronic progressive multiple sclerosis
BACKGROUND Preclinical studies have demonstrated that MIS416, a bacterially derived immune modulator, targets myeloid cells following systemic delivery. MIS416 stimulated myeloid cells have the capacity to regulate innate inflammation, a potential therapeutic target for progressive multiple sclerosis. OBJECTIVES To determine the safety, tolerability, pharmacodynamics and maximum tolerated dos...
متن کاملCladribine in aggressive forms of multiple sclerosis.
Cladribine (2-chlorodeoxyadenosine) is an immunosuppressant drug previously evaluated in multiple sclerosis (MS) with variable results. We report six patients with aggressive relapsing MS who despite a poor response to other therapies had a favourable clinical evolution after cladribine. Four women and two men with a rapid increase in the number and severity of relapses leading to increasing di...
متن کاملCladribine in the treatment of multiple sclerosis
ISSN 2041-6792 10.4155/CLI.10.32 © 2011 Future Science Ltd Treatment with cladribine leads to a preferential and sustained reduction in lymphocytes and monocytes, resulting in long-lasting depletion of CD4+ and CD8+ T cells. In the Phase III placebo-controlled trial in relapsing–remitting multiple sclerosis (the CLARITY study), oral cladribine at 96 weeks significantly reduced annual relapse ra...
متن کاملCladribine to treat disease exacerbation after fingolimod discontinuation in progressive multiple sclerosis
Rebound disease following cessation of disease modifying treatment (DMT) has been reported in people with both relapsing and progressive multiple sclerosis (pwRMS, pwPMS) questioning strict separation between these two phenotypes. While licensed DMT is available for pwRMS to counter rebound disease, no such option exists for pwPMS. We report on a pwPMS who developed rebound disease, with 45 Gad...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
سال: 1998
ISSN: 0317-1671,2057-0155
DOI: 10.1017/s0317167100034302